Liver Resection for Colorectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Microspheres: A Systematic Review
暂无分享,去创建一个
[1] V. Gebski,et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials , 2017, The Lancet. Oncology.
[2] M. Baltatzis,et al. Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: a systematic review. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[3] S. Kopetz,et al. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] J. Guinney,et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.
[5] V. Gebski,et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] K. Haustermans,et al. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival , 2016, Acta oncologica.
[7] J. Burns,et al. Selective internal radiation therapy for liver malignancies , 2015, The British journal of surgery.
[8] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[9] K. Tatsch,et al. Liver resection after selective internal radiotherapy (SIRT): Proof of concept, initial survival, and safety , 2015, Journal of surgical oncology.
[10] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.
[11] S. Jegatheeswaran,et al. Management of colorectal cancer presenting with synchronous liver metastases , 2014, Nature Reviews Clinical Oncology.
[12] Ricky A. Sharma,et al. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases , 2012, Journal of Clinical Pathology.
[13] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[15] B. Sangro,et al. Radioembolization for Hepatocellular Carcinoma: Evidence-Based Answers to Frequently Asked Questions , 2011 .
[16] K. McMasters,et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. , 2011, The Journal of surgical research.
[17] E. Van Cutsem,et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Ducreux,et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Benson,et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. , 2007, International journal of radiation oncology, biology, physics.
[20] P. Gibbs,et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Lepage,et al. Epidemiology and Management of Liver Metastases From Colorectal Cancer , 2006, Annals of surgery.
[22] G. Launoy,et al. A population‐based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer , 2006, The British journal of surgery.
[23] P. Gibbs,et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy , 2005, BMC Cancer.
[24] Bernard Paule,et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.
[25] W. Ensminger. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. , 2002, Seminars in oncology.
[26] V. Gebski,et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] F. Lévi,et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. , 1996, Annals of surgery.